Vistin Pharma ASA : Proposal for Extraordinary Dividend


09.10.17 14:35
Meldung
 
Vistin Pharma ASA : Proposal for Extraordinary Dividend

Oslo, Norway, 9 October 2017

Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Board of Vistin Pharma will propose an extraordinary dividend of NOK 7.00 per share.

On 2 October, the Company announced the successful completion of the sale of its opioids and tablet manufacturing business to TPI Enterprises Limited, which resulted in the receipt of a provisional cash consideration of NOK 159.5 million. The sale is expected to have a positive net cash effect of NOK 140 - 150 million, before any transaction costs. As a result of this sale, the Board will call for an extraordinary general meeting to approve a dividend of NOK 7.00 per share (NOK 119.4 million).

Following the sale, Vistin Pharma is a pure play metformin producer, with a strong position in the global metformin market. The global market for metformin is expected to grow by four to five percent per annum, and Vistin Pharma is attractively positioned to capture part of this growth. The Company's project to double the production capacity for metformin is progressing according to plan, and the project will be presented in further details in the third quarter financial report to be released on 27 October.

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

kjell-erik.nordby@vistin.com

Gunnar Manum

CFO

+47 95 17 91 90

gunnar.manum@vistin.com 

 
 
 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vistin Pharma ASA via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

VISTIN PHARMA ASA NK 1

Aktuelle Diskussionen zum Thema:


Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

VISTIN PHARMA ASA NK 1
Weitere Meldungen
 
10.10 XPO Logistics to Ring Open.
10.10 INGENICO GROUP: Q3 REV.
10.10 Ad hoc: paragon AG: E-Mob.
10.10 Ad hoc: Voltabox AG legt .
10.10 Metso wins a significant ord.
10.10 Aker Solutions ASA: Invitat.
10.10 XPO Logistics Expands Data.
10.10 Elanders AB: Elanders make.
10.10 Medtronic to Establish Innov.
10.10 Biocartis Group NV: Disclosu.
09.10 Ad hoc: WILEX AG gibt Ä.
09.10 CORRECTION: Össur hf: Q3.
09.10 Össur hf: Q3 2017 Results .
09.10 LVMH: 12% ORGANIC REV.
09.10 Arcadis reports transactions.
09.10 Ageas reports on the progr.
09.10 Ad hoc: technotrans-Gruppe .
09.10 Ad hoc: Francotyp-Postalia .
09.10 Eastman Updates Full-Year 2.
09.10 Vistin Pharma ASA : Propo.
09.10 Net Insight AB: Net Insight .
09.10 Cargotec's financial informat.
09.10 Ad hoc: Holmes Investment .
09.10 Ad hoc: Correction of a rele.
09.10 Ad hoc: SAF-HOLLAND S.A.
09.10 Stolt-Nielsen Limited Reports.
09.10 Ad hoc: DIC Asset AG pla.
09.10 SCOR estimates the cost o.
06.10 New large TITANĀ® order fo.
06.10 Ad hoc: Holmes Investment .


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 43371 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Wirecard: Erste Hürde genommen!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
MDAX: Der bessere DAX?
Robert Schröder, Elliott-Waves.com (12.12.18)
Experte: Robert Schröder, Elliott-Waves.com
Wirecard-Doppel für mobile ...
Jörg Schulte, JS-Research (12.12.18)
Experte: Jörg Schulte, JS-Research
WTI Öl - Der Abverkauf ...
Philip Hopf, Hopf Klinkmüller Capital. (12.12.18)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
DOW DAX an der Trendlinie
Thomas Heydrich, Systemstradings.de (12.12.18)
Experte: Thomas Heydrich, Systemstradings.de
DAX macht weiter Boden ...
CMC Markets, (12.12.18)
Experte: CMC Markets,
Bayer: Blick auf Details!
Robert Sasse, (12.12.18)
Experte: Robert Sasse,
S&P500 - 2.700 Punkte ...
Christian Zoller, www.boerse-daily.de (12.12.18)
Experte: Christian Zoller, www.boerse-daily.de
ETFs: Setzen auf ...
Redaktion boerse-frankf., Deutsche Börse AG (12.12.18)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
Gold braucht vor wirklicher ...
Björn Junker, GOLDINVEST.de (12.12.18)
Experte: Björn Junker, GOLDINVEST.de
VW: Interessante ...
Volker Gelfarth, (12.12.18)
Experte: Volker Gelfarth,
Entspannung im ...
Cornelia Frey, Börse Stuttgart AG (12.12.18)
Experte: Cornelia Frey, Börse Stuttgart AG
Amazon – zuschlagen und ...
Feingold-Research, (12.12.18)
Experte: Feingold-Research,
Niquet's World
Neues vom Portal
 
Die Geldanlage: Eine kleine Einführung
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen